Octinoxate
Shade Uvaguard (octinoxate) is a small molecule pharmaceutical. Octinoxate was first approved as Shade uvaguard on 1992-12-07.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| abalone crystaldouble ex bb | unapproved drug other | 2017-03-10 |
| abalone crystaldouble ex cc | unapproved drug other | 2017-03-10 |
| alba botanica natural very emollient sunscreen kids spf40 | OTC monograph final | 2012-05-03 |
| alba botanica natural very emollient sunscreen spf40 | OTC monograph final | 2012-04-30 |
| alba botanica natural very emollient sunscreen sport spray spf40 | OTC monograph final | 2012-05-08 |
| alba hawaiian green tea sunblock spf 45 | OTC monograph not final | 2010-07-13 |
| alba lip care sunblock spf 25 | OTC monograph not final | 2010-07-26 |
| alba sunblock natural kids spf 45 | OTC monograph not final | 2010-07-09 |
| alba sunblock natural lavender spf 45 | OTC monograph not final | 2010-07-06 |
| alba sunblock natural sport spf 45 | OTC monograph not final | 2010-07-06 |
Show 160 more
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| photosensitivity disorders | HP_0000992 | D010787 | L57.1 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
8 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dermatitis | D003872 | HP_0011123 | L30.9 | — | — | — | 1 | 1 | 2 |
| Melanosis | D008548 | HP_0001480 | L81.1 | — | — | — | 1 | — | 1 |
| Allergic contact dermatitis | D017449 | — | L23 | — | — | — | 1 | — | 1 |
| Contact dermatitis | D003877 | — | L25 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sun protection factor | D059405 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
No data
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Skin aging | D015595 | EFO_0005422 | — | 1 | — | — | — | — | 1 |
| Skin neoplasms | D012878 | EFO_0004198 | C44 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Photoallergic dermatitis | D017454 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Octinoxate |
| INN | octinoxate |
| Description | Octyl 4-methoxycinnamic acid is a cinnamate ester. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCCCC(CC)COC(=O)C=Cc1ccc(OC)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 5466-77-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3183184 |
| ChEBI ID | — |
| PubChem CID | 5355130 |
| DrugBank | — |
| UNII ID | 4Y5P7MUD51 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 542 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
11,968 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use